DTU Logo
Overview | 4-T | ACE | ADOPT | AFORRD | DREAM | EDIT | EXSCEL | FHS | GLINT | ISAT | LDS | NAVIGATOR | TECOS | UKPDS

Trial Evaluating Cardiovascular Outcomes With Sitagliptin

TECOS logo


Publications (7 of 15)


Search Publications :

In-press or Epub

Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease
Mostafa SA, Coleman RL, Agbaje OF, Gray AM, Holman RR, Bethel MA
Diabet Med. 2017. Epub:23-Oct-2017. PMID:29057545. doi:10.1111/dme.13533

2017

Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial
Abhinav Sharma, Jennifer B. Green, Allison Dunning, Yuliya Lokhnygina, Sana M. Al-Khatib, Renato D. Lopes, John B. Buse, John M. Lachin, Frans Van de Werf, Paul W. Armstrong, Keith D. Kaufman, Eberhard Standl, Juliana C.N. Chan, Larry A. Distiller, Russell Scott, Eric D. Peterson, and Rury R. Holman, on behalf of the TECOS Study Group
Diabetes Care 2017;40:1763-1770. Published:Dec-2017. Epub:06-Oct-2017. PMID:28986504. doi:10.2337/dc17-1091

Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin
Navar AM, Gallup DS, Lokhnygina Y, Green JB, McGuire DK, Armstrong PW, Buse JB, Engel SS, Lachin JM, Standl E, Van de Werf F, Holman RR, Peterson ED
Hypertension 2017;70:907-914. Published:Nov-2017. Epub:28-Aug-2017. PMID:28847886. doi:10.1161/HYPERTENSIONAHA.117.09482

Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Outcomes from TECOS
Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, Riefflin A, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group
Diabetes Obes Metab. 2017;19:1587–1593. Published:Nov-2017. Epub:22-Apr-2017. PMID:28432745. doi:10.1111/dom.12983

Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International 2 Insights from the TECOS Trial
Neha J. Pagidipati, Ann Marie Navar, Karen S. Pieper, Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong, Robert G. Josse, Darren K. McGuire, Yuliya Lokhnygina, Jan H. Cornel, Sigrun Halvorsen, Timo E. Strandberg, Tuncay Delibasi, Rury R. Holman, Eric D. Peterson, On behalf of the TECOS Study Group
Circulation 2017;136:1193–1203. Published:26-Sep-2017. Epub:16-Jun-2017. PMID:28626088. doi:10.1161/CIRCULATIONAHA.117.027252

Corrections needed to 2016 ESC and AHA guidelines on heart failure
Lars Rydén, Frans Van de Werf, Paul W Armstrong, Darren K McGuire, Eberhard Standl, Eric D Peterson, Rury R Holman
Lancet Diabetes Endocrinol. 2017;5:325-326. Published:May-2017. Epub:05-Apr-2017. PMID:28395875. doi:10.1016/S2213-8587(17)30102-X

Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS)
M. Angelyn Bethel, Samuel S. Engel, Jennifer B. Green, Zhen Huang, Robert G. Josse, Keith D. Kaufman, Eberhard Standl, Shailaja Suryawanshi, Frans Van de Werf, Darren K. McGuire, Eric D. Peterson, Rury R. Holman, for the TECOS Study Group
Diabetes Care 2017;40:494–501. Published:Apr-2017. Epub:05-Jan-2017. PMID:28057693. doi:10.2337/dc16-1135